BRISBANE, AUSTRALIA--(Marketwired - March 03, 2014) - Alchemia Limited (ASX: ACL), a drug discovery and development company, today announced that Thomas Liquard, the Company's Chief Executive Officer, will present a corporate overview at the 26th Annual ROTH Conference. Mr Liquard's presentation will take place on Wednesday, March 12th, 2014 at 10:00AM PST at The Ritz Carlton in Dana Point, California.
Slides from the presentation will be posted to the ASX and available on Alchemia's website at http://www.alchemia.com.au at the time of the presentation.
About Alchemia Limited
Alchemia is a drug discovery and development company marketing FDA approved fondaparinux, an injectable antithrombotic in the US, as well as other major markets via partner Dr. Reddy's Laboratories. The Company is also developing a late stage oncology product pipeline with multiple ongoing trials through its proprietary HyACT drug delivery platform, which targets anti-cancer drugs to solid tumours. Lead asset HA-Irinotecan is in a pivotal Phase III clinical trial for the treatment of metastatic colorectal cancer. HA-Irinotecan is also in two Phase II investigator-sponsored trials, one of which is in collaboration with Merck Serono combining HA-Irinotecan with Erbitux® (cetuximab). Alchemia is also exploring additional small molecule drug discovery targets via an internal discovery platform VAST, based on the Company's deep chemistry expertise. The VAST technology is being developed in collaboration with leading academic institutions and is partnered with AstraZeneca AB.
Arixtra® is a trademark of GlaxoSmithKline plc, Erbitux® is a trademark of Merck KGaA.